A physician-led initiative focused on earlier detection, structured prevention, and long-term cardiovascular risk reduction. Founded by Dr. Francesco Lo Monaco.
#1
Cardiovascular disease is the leading cause of death globally
Many
First cardiac events occur with no prior diagnosis of heart disease
Decades
Atherosclerosis develops silently — creating a window for intervention
About the Institute
A structured approach to cardiovascular prevention
The Heart Savior Institute is a physician-led initiative focused on advancing a more proactive and structured approach to cardiovascular prevention. Its work is centered on identifying risk earlier, applying targeted interventions, and managing disease over time — before the first clinical event occurs.
The Institute brings together a clinical framework, physician education, and a growing network of practitioners who share a focus on prevention.
Cardiovascular disease remains the leading cause of death globally. In many cases, the first manifestation is a heart attack or stroke in individuals never previously diagnosed. A more effective model requires earlier detection and a structured approach to long-term management.
A Clinical Framework
A structured approach to detecting and managing cardiovascular risk, built around the Heart Savior Protocol.
Physician Education
CME-accredited modules, case-based learning, and implementation guidance for practical application in daily practice. Launching early 2027. Patient education resources to follow.
A Physician Network
A growing group of clinicians focused on early detection and long-term risk management, supporting collaboration.
Why This Work Matters
The prevention gap is a solvable problem
The science of early identification exists. The clinical tools exist. What has been missing is a structured approach to applying them consistently — before the first event, not after.
Detect
Atherosclerosis can be identified years before symptoms appear using imaging and targeted biomarkers. Most patients never receive that assessment.
Define
Risk is not uniform. Lipid burden, metabolic dysfunction, and inflammation each contribute differently. Identifying the specific drivers changes what treatment looks like.
Act
Earlier detection without structured, long-term management does not change outcomes. The gap is not just in diagnosis — it is in sustained clinical follow-through.
The Heart Savior Protocol
A structured approach to prevention
A framework for applying existing tools earlier, more systematically, and with ongoing monitoring over time.
01
Detect
Identify atherosclerosis early using imaging and biomarkers, beyond risk estimation alone.
02
Define
Determine the primary drivers of disease — lipid, metabolic, and inflammatory risk.
03
Personalize
Develop a targeted strategy based on identified risk, including lifestyle and pharmacologic options.
04
Stabilize
Apply consistent management to reduce plaque progression and long-term risk.
05
Monitor
Follow patients longitudinally using biomarkers, imaging, and clinical evaluation.
The Heart Savior Protocol is not a guideline. It is a framework for applying preventive cardiology in a consistent and practical way.
Founder
Dr. Francesco Lo Monaco
Dr. Francesco Lo Monaco
Preventive Cardiologist · Harley Street, London
Global Cardiologist of the Year Award Fluxx Conference, Qatar 2025
European Awards in Medicine Patient Care & Cardiology 2022, 2024 & 2025
NHS Consultant Cardiologist
Medical Training: Italy, UK, USA
Dr. Lo Monaco is a multi-award-winning, internationally trained cardiologist with a focus on preventive cardiovascular medicine. His clinical work has emphasized the early detection of atherosclerosis and the management of long-term cardiovascular risk before the onset of symptoms.
With training across Europe and the United States and a private practice on Harley Street in London, his experience reflects a broad perspective on both public and private healthcare systems. The Heart Savior Institute is an extension of this clinical focus toward a more structured and scalable model of prevention.
Why Patients With No Prior Diagnosis Experience a First Heart Attack
Risk estimation and disease detection are not the same thing.
Imaging
What CAC Scoring Actually Tells Us
A CAC score measures evidence of atherosclerosis — not risk in the abstract.
Lipid Management
ApoB vs LDL: What Actually Matters
Two patients with similar LDL can have very different cardiovascular risk.
An evolving model. An open invitation.
The Heart Savior Institute is currently in active development. Physicians who share an interest in structured cardiovascular prevention are welcome to reach out to learn more.
Stay Informed
Insights in preventive cardiology and updates from the Institute. No promotional emails.
The Heart Savior Protocol
A structured approach to detecting and managing atherosclerosis before the first clinical event.
Many physicians already apply elements of prevention. The difference is applying them earlier, more consistently, and in a structured way.
The Problem
Risk estimation and disease detection are not the same thing. A patient may score as moderate risk and still have significant atherosclerosis already present.
The Approach
Move from estimating future risk to determining current disease status. The protocol integrates both perspectives as a guide to structured, long-term management.
01
Detect
Early Disease Identification
Identify atherosclerosis before symptoms develop, not after. Standard cardiovascular risk assessment estimates the probability of a future event. It does not determine whether disease is already present. A patient may carry a moderate risk score and still have significant subclinical atherosclerosis.
This requires a deliberate choice to look earlier than symptoms demand, using imaging and targeted biomarkers to determine the actual state of the arterial wall rather than inferring it from population-level variables.
Risk estimation predicts probability. Imaging and targeted biomarkers identify presence. Both are needed. But the second changes clinical decision-making in ways the first cannot.
Relevant Tools & Approaches
CAC ScoringCarotid IMTApoBLipoprotein(a)hsCRP
02
Define
Driver Identification
Understand the specific factors contributing to disease in each patient. Atherosclerosis is not driven by a single pathway. Lipid-related risk, metabolic dysfunction, inflammation, insulin resistance, and other factors each contribute differently across patients.
This step moves beyond the standard lipid panel to a more complete picture of atherogenic burden — one that can distinguish between a patient whose risk is primarily driven by particle number and one whose risk is predominantly metabolic.
Two patients with similar LDL levels may have very different ApoB levels. In those cases, atherogenic burden is not equivalent, and the treatment strategy should not be either.
Develop a prevention strategy based on identified risk, not population averages. Preventive cardiology becomes more effective when it is built around what is actually driving disease in a specific patient.
That strategy may include lifestyle intervention, pharmacologic therapy, or both. Treatment goals are derived from the individual's risk profile and disease status, and are specific enough to be measurable and adjustable over time.
The objective is not simply to bring a value within a reference range. It is to reduce the specific drivers of atherosclerosis in that patient to a level that meaningfully alters their long-term trajectory.
Focus on reducing progression and long-term risk, not only treating values. Once a targeted intervention is in place, the objective shifts to stabilization — reducing plaque progression and managing underlying risk factors consistently over time.
Stabilization means holding achieved gains, addressing new risk factors as they emerge, and maintaining a treatment intensity that reflects the patient's actual disease burden.
The goal is not only treatment. It is long-term risk reduction. Those are related but not identical objectives.
Relevant Tools & Approaches
Plaque StabilizationPharmacologic ManagementMetabolic MonitoringAdherence Support
05
Monitor
Longitudinal Follow-Up
Prevention is not a single intervention. It is a process that requires ongoing clinical attention. Disease trajectories change. Risk factors evolve. Responses to treatment vary.
Monitoring provides the data needed to determine whether interventions are working, whether disease is progressing, and whether treatment goals remain appropriate. It transforms a one-time clinical assessment into a managed, long-term program of cardiovascular care.
Prevention is dynamic. A framework that does not include structured longitudinal follow-up is not a prevention program. It is an assessment.
Relevant Tools & Approaches
Serial Biomarker AssessmentRepeat ImagingClinical Follow-Up ScheduleTreatment Goal Review
Positioning
Not a guideline. A framework for clinical practice.
Applicable across cardiology, internal medicine, and primary care
Designed to complement existing clinical workflows
Builds on established tools, applied earlier and more consistently
Structured for long-term patient management, not one-time assessment
Stay Informed
Insights in preventive cardiology and updates from the Institute.
For Physicians
A structured approach to prevention, designed for clinical practice.
Many physicians already incorporate elements of prevention. The challenge is applying those elements consistently, systematically, and early enough to change outcomes.
The Challenge
The challenge is not lack of knowledge. The gap lies in how consistently and how early those principles are applied in practice. By the time symptoms appear, the disease process is already well established.
The Opportunity
There is an important distinction between estimating the likelihood of developing atherosclerosis and determining whether it is already present. As diagnostic tools improve, there is increasing opportunity to shift from estimation to detection.
The Protocol in Practice
A structured framework for earlier intervention
01
Detect
Identify atherosclerosis early using imaging and biomarkers.
02
Define
Determine the primary drivers of disease in each patient.
03
Personalize
Develop a targeted strategy based on identified risk.
04
Stabilize
Consistent management to reduce progression and long-term risk.
05
Monitor
Follow patients longitudinally using biomarkers and imaging.
What the Institute Provides
Resources built for clinical application
Structured Education
CME-accredited modules, case-based learning, and implementation guidance. Launching early 2027. Patient education resources to follow.
Physician Network
A growing network of physicians focused on early detection and long-term risk management, supporting collaboration and shared protocol development.
Clinical Framework
A repeatable structure applicable across cardiology, internal medicine, and primary care, complementing existing workflows.
Why Physicians Engage
A shared focus on prevention
Focused on prevention as a core part of their practice, not an afterthought to acute care.
Interested in earlier identification of atherosclerosis, before the first clinical event.
Looking for a more structured and consistent approach to long-term cardiovascular risk management.
Seeking a professional community with a shared clinical orientation toward prevention.
Interested in contributing to a model of care that can be applied and refined across different clinical settings.
"The challenge is not that prevention is unknown. It is that it is often applied inconsistently, and frequently later than it could be."
Dr. Francesco Lo Monaco · Founder, Heart Savior Institute
Request Access
Physician Inquiry
Physicians interested in the Institute's work are welcome to reach out. There is no single model of participation.
We will only contact you with relevant Institute updates.
Stay Informed
Insights in preventive cardiology and updates from the Institute.
Insights
Clinical perspectives on prevention.
Short analyses on the science, practice, and limitations of preventive cardiology. Written for clinicians and informed patients. No editorial agenda. No sponsored content.
01
Risk Assessment
Why Patients With No Prior Diagnosis Experience a First Heart Attack
The limitation is not in prediction. It is in how risk is assessed. Risk estimation and disease detection are not the same thing. Traditional models rely heavily on risk estimation — age, cholesterol levels, blood pressure — combined into a score. These models are useful, but they do not determine whether atherosclerosis is already present.
Risk estimation predicts probability. Imaging and targeted biomarkers identify presence. Preventive cardiology becomes more effective when the focus shifts from estimating future risk to determining whether disease already exists.
Clinical Application
Move from probability to presence in clinical decision-making
Apply imaging earlier, before symptoms present
Use biomarkers to identify disease that risk scores miss
02
Imaging
What CAC Scoring Actually Tells Us
A CAC score does not measure risk in the abstract. It measures evidence of atherosclerosis. That distinction changes clinical decision-making. A score of zero suggests that calcified plaque is not yet present. A positive score confirms that atherosclerosis has already developed.
CAC shifts the conversation from probability to presence. Used appropriately, it can help refine treatment decisions, guide intensity of therapy, and improve patient understanding.
Clinical Application
Refine treatment decisions
Guide intensity of therapy
Improve patient understanding of disease presence
03
Lipid Management
ApoB vs LDL: What Actually Matters
Two patients can have similar LDL levels and very different ApoB levels. In those cases, risk is not equivalent. Each atherogenic particle carries one ApoB molecule. Measuring ApoB gives a direct estimate of the total number of particles capable of contributing to plaque formation.
The objective is not to replace LDL, but to refine how lipid-related risk is understood and managed.
Clinical Application
Better risk stratification
More targeted therapy
Clearer, more individualized treatment goals
04
Prevention & Systems
Why Prevention Often Happens Too Late
In many healthcare settings, cardiovascular disease is managed after it becomes clinically apparent. But atherosclerosis develops over decades. Symptoms drive evaluation, and acute events demand immediate attention. By the time symptoms appear, the disease process is already well established.
The challenge is not that prevention is unknown. It is that it is often applied inconsistently, and frequently later than it could be.
Clinical Application
Identifying disease before symptoms develop
Understanding the specific drivers in each patient
Managing risk consistently over time
05
Risk Assessment
From Risk Estimation to Disease Detection
Individual patients do not experience probabilities. They experience disease. There is an important distinction between estimating likelihood and determining presence. Much of modern cardiovascular care is built around estimating risk — valuable at a population level, but not the same as determining whether disease already exists.
As diagnostic tools improve, there is increasing opportunity to shift from estimation to detection.
Clinical Application
Risk estimation as a population-level guide
Disease detection as the basis for individual clinical decisions
Integration of both for more precise and effective care
Stay Informed
Insights in preventive cardiology and updates from the Institute.
Books
The clinical thinking behind the Institute.
Two books by Dr. Francesco Lo Monaco, written for physicians and informed patients.
Heart Savior
A Preventive Cardiologist's Step-By-Step Guide to Lasting Heart Health and Longevity
Most heart attacks are not sudden. They are the result of a decade of mixed signals — risk factors identified but not acted on, disease present but not detected, prevention acknowledged but not structured. Heart Savior lays out the case for acting earlier in over 400 pages of comprehensive cardiovascular prevention material, covering cardiovascular risk, metabolic health, imaging, lifestyle, and the interventions that actually change outcomes.
For Physicians
A structured perspective on applying preventive cardiology in clinical practice, with an emphasis on early detection and long-term risk management.
For Individuals
A clear explanation of how cardiovascular disease develops and how a more proactive approach to prevention can improve long-term outcomes.
Key Themes
Why many first heart attacks occur without prior diagnosis
The limitations of traditional risk estimation
The role of biomarkers and imaging in early detection
The importance of structured, long-term management
Pre-Order · Coming 2027
The Practical Path
A Physician's Case for Incremental Reform of American Healthcare
The Practical Path explores how meaningful healthcare reform can be achieved through structured, incremental change rather than large-scale disruption. Drawing on clinical experience across multiple healthcare systems, the book examines how targeted, practical reforms can improve access, reduce costs, and strengthen long-term outcomes.
A Different Way to Approach Reform
A more practical question: what changes can be implemented within the current system that would meaningfully improve outcomes? This shift — from ideal design to practical implementation — moves the focus from theory to execution.
About the Author
Dr. Francesco Lo Monaco
Preventive Cardiologist · Harley Street
Global Cardiologist of the Year Award Fluxx Conference, Qatar 2025
European Awards in Medicine Patient Care & Cardiology 2022, 2024 & 2025
Dr. Lo Monaco is an award-winning, internationally trained cardiologist with a focus on preventive cardiovascular medicine. With training across Europe and the United States and a private practice on Harley Street in London, his work reflects a broad perspective on cardiovascular care across systems, populations, and the boundary between clinical practice and policy.
